GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Intellia Therapeutics Inc (LTS:0JBU) » Definitions » Inventories, Other

Intellia Therapeutics (LTS:0JBU) Inventories, Other : $0.00 Mil (As of Mar. 2024)


View and export this data going back to 2018. Start your Free Trial

What is Intellia Therapeutics Inventories, Other?

Other inventories including goods for resale, stocks in transit, consignment stocks, etc. Intellia Therapeutics's other inventories for the quarter that ended in Mar. 2024 was $0.00 Mil.


Intellia Therapeutics Inventories, Other Historical Data

The historical data trend for Intellia Therapeutics's Inventories, Other can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Intellia Therapeutics Inventories, Other Chart

Intellia Therapeutics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Inventories, Other
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Intellia Therapeutics Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Inventories, Other Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Intellia Therapeutics Inventories, Other Calculation

Other inventories including goods for resale, stocks in transit, consignment stocks, etc.


Intellia Therapeutics (LTS:0JBU) Business Description

Traded in Other Exchanges
Address
40 Erie Street, Suite 130, Cambridge, MA, USA, 02139
Intellia Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. Intellia is focused on using this technology to treat genetically defined diseases. It's evaluating multiple gene editing approaches using in vivo and ex vivo therapies to address diseases with high unmet medical needs, including ATTR amyloidosis, hereditary angioedema, sickle cell disease, and immuno-oncology. Intellia has formed collaborations with several companies to advance its pipeline, including narrow-moat Regeneron and wide-moat Novartis.

Intellia Therapeutics (LTS:0JBU) Headlines

No Headlines